Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment

Gynecologic Oncology

Volumn 86, Issue 3, 2002, Pages 239-243

  Heddens, David ^a   Alberts, David S ^a   Hannigan, Edward V ^b   Williams, Steven D ^c   Garcia, Dava ^a   Roe, Denise J ^a   Bell, Jeffrey ^d   Alvarez, Ronald D ^e  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c INDIANA UNIVERSITY   (United States)

^d RIVERSIDE METHODIST HOSPITAL   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PLATINUM;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 0036446093     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6726     Document Type: Article

References (23)

1. Greenlee RT, Murray T, Bolden S, Wingo PA, Cancer statistics, 2000. Ca: Cancer J Clin 2000;50(1):7-33.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6.
3. Ozols RF, Bundy BN, Clarke-Pearson D, Mannel R, Hartenbach EM, Baergen R. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARB)/PAC in optimal stage III epithelial ovarian cancer (OC) Gynecologic Oncology Group (GOG 158). Proc Am Soc Clin Oncol 1999;18:356a.
4. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott Williams & Wilkins; 2000.
5. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91(19):1616-34.
6. Lhomme C, Kerbrat P, Lejeune C, Guastalla JP, Fumoleau P, Goupil A, Heron JF, Cassin MA, Pruvot I, Soares JA, Chazard M. Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: Preliminary results of a phase I study. Semin Oncol 1996;23(5 Suppl 12):48-54.
7. Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 1997;15(5):1953-64.
8. Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr, Barakat R, Curtin J, Almadrones L, Hoskins W. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993;49(2):172-6.
9. Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, Sevelda P. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997;65(3):461-6.
10. Pavel JN. Red blood cell transfusions for anemia. Semin Oncol Nurs 1990;6(2):117-22.
11. Skolnick AA. Transfusion medicine faces time of major 'challenges and changes.' JAMA 1992;268(6):697.
12. Zuck TF. Greetings-a final look back with comments about a policy of a zero-risk blood supply. Transfusion 1987;27(6):447-8.
13. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 1994;12(5):1058-62.
14. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M, Rosso R. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997;15(7):2715-21.
15. Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophos-phamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 1993;50(Suppl 2)2-9.
16. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335(26):1950-5.
17. Lawless JF. Statistical Models and Methods for Lifetime Data. New York: Wiley; 1982.
18. Agresti A. Categorical Data Analysis. New York: Wiley; 1990.
19. Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology 1995;52(5):422-6.
20. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16(10):3412-25.
21. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994;73(10):2535-42.
22. ten Bokkel Huinink WW, de Swart CA, van Toorn CA, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15(3):174-82.
23. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, Gordon MS, Lichtin AE, Wade JL 3rd, Woolf S, Aronson N. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93(16):1204-14.